Education

Dr. Arvind Dasari reviews how the current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy. https://youtu.be/Fzu48PE5V_Q

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer. https://www.onclive.com/view/dr-morris-on-the-investigation-of-the-role-of-ctdna-in-stage-ii-crc

Dr. Arvind Dasari reviews the reported results of the DYNAMIC study, in which a circulating tumor DNA (ctDNA)-guided approach reduced the use of adjuvant chemotherapy without compromising recurrence-free survival in patients with stage II colon cancer.

Dr. Alisha Bent, Assistant Professor of Gastrointestinal Medical Oncology at University of Texas MD Anderson Cancer Center introduces a clinical trial, The Daily Study.  This study aims to uncover the impact of intensive lifestyle interventions in the setting of colorectal cancers and with the use of ctDNA surveillance. ClinicalTrials.gov Identifier: NCT05036109 Dr. Alisha Bent, Assistant Professor of Gastrointestinal Medical Oncology at University of Texas MD Anderson Cancer Center introduces The Daily Study, an intensive lifestyle intervention study.

Dr. Mike Overman discusses the reported results of the DYNAMIC study with Dr. Jeanne Tie in this ASCO Post video, in which a circulating tumor DNA (ctDNA)-guided approach reduced the use of adjuvant chemotherapy without compromising recurrence-free survival in patients with stage II colon cancer.

n this DocTalk, Dr. Chris Lieu goes over CRC screening tests, including newer DNA-based tests that focus on CRC and multi-cancer early detection tests, designed for patients without a history of colon cancer. In the second part of his talk, he covers the CIRCULATE-US trial for high-risk stage II and III colon cancer patients, which as of May 2022 is currently enrolling. This trial will address questions around the clinical utility of Minimal Residual Disease ctDNA testing. More details on this study are available here. Please see the Lecture Hall in ColonTown for more great content on colorectal cancer! Many [...]

Circulating tumor DNA can be used to define minimal residual disease after resection of liver metastases.  Despite surgical resection, the rates of recurrence (and post-operative minimal residual disease) are higher in this setting (stage IV) than in early stages of the disease.  Here from expert Tim Newhook, a hepatobiliary surgeon with expertise in colorectal liver metastases and ctDNA, on the the potential for ctDNA to provide prognostic information and potentially guide therapy.  Additionally, learn how ctDNA may be used to enroll into novel clinical trials. https://youtu.be/3t-Hvct1ZpM Table of contents 00:00: Introduction 00:45: Dr. Newhook tells us about his path [...]

Circulating tumor DNA can be a bit mystifying. A number of clinical trials are being initiated (check out the current listings here) and there are questions about how to use these assays in clinical management now. Thanks to Colontown University for hosting a Doc Talk on this, where a number of important topics are covered, including minimal residual disease, single tests vs multiple tests, recent updates from GI ASCO conference, a number of ongoing clinical trials, and the INTERCEPT program ongoing at MD Anderson. https://www.youtube.com/watch?v=DmycTmNgzps In this Doc Talk, I discuss a number of frequently asked questions, including: [...]